Treatment of plasma cell disorders has dramatically improved during the past decade as a result of the availability of new biology-based drugs, such as proteasome inhibitors and immunomodulatory agents. With increased attention to disease biology, however, it has become clear that there are many different subsets of patients with myeloma with different biologic drivers as well as different patient-based characteristics that can influence treatment. Obtaining initial genetics or genomics information can provide some of the information needed to define therapy after initial induction, and careful performance status assessment can help to define patient-specific characteristics that are important when determining the intensity of therapy. Careful assessment of both can help to optimize therapy type and duration for all patients and to improve long-term outcomes.
INTRODUCTION
A common theme among all cancers is that whereas routine light microscopy of a given disease seems to identify a homogeneous group of patients, these similar diseases often have wide variations in genetics and mutational profiles. Multiple myeloma is no different. Although plasma-cell disorders may look microscopically similar, we know that by using cytogenetics or fluorescence in situ hybridization (FISH) testing, 1,2 several subtypes of myeloma have been identified. When more advanced technologies, such as gene expression profiling (GEP) [3] [4] [5] or RNA-and DNA-based sequencing, are used, 6 between five and 20 different types of myeloma appear, each potentially phenotypically different in their clinical behavior and response to therapy. When this genetic landscape is further complicated by the intrinsic clonal heterogeneity 7 that is present even before treatment starts, the disease, frankly, becomes molecularly depressing, and the clinician loses hope that control of the disease can be obtained or that any discussion of cure can be had. However, as clinicians, we all know that there are in fact patients who can do quite well for extended periods, with median survival times in excess of 10 years, and, perhaps, 10% to 15% of patients are even cured. 8 Furthermore, even among high-risk patients, there are subsets that can do well for a long time with new treatments, 9 further calling into question the gloom and doom associated with complex sequencing data sets that are reported now. How, then, is the busy clinician to reconcile the dichotomy of, on the one hand, a complicated molecular disease with progressive genomic instability and, on the other hand, clinical experience that suggests some patients can do well and a subset can achieve long-term durable remission or even cure? The obvious answer is that not all patients with myeloma are the same and that perhaps there is a role for tailored therapy; however, at what point should the therapy be different (diagnosis v maintenance), and do we know enough about the biologic differences to treat them differently? What are the criteria for approaching treatment differently, and how does the goal or end point of therapy change with this modification?
DETERMINING PATIENT OUTCOME For patients with myeloma, there are two major discriminators of outcome that have major independent implications for survival: functional status and genetics. These two assessments are likely key to further outlining how patients will be treated, and, to take this one step further, functional assessment is an important early driver as it determines the intensity of therapy. To rephrase, early treatment mortality, and, thus, failure, is driven by both frailty (eg, patients unable to tolerate treatment) and by genetics; therefore, careful attention to therapy intensity, while addressing the genomic heterogeneity between patients with standard and high-risk myeloma, is needed as one administers less-intensive therapy in the frail patient.
Functional Status Assessment
Assessment of functional status has been performed by using a number of different tools, from the subjective eyeball test by clinicians, to more objective instruments, such as the Charlson Comorbidity Index, 10 the Freiburg Comorbidity Index, 11, 12 the Hematopoietic Cell Transplantation-Comorbidity Index, 13 or the recently published Frailty Index. 14 The advantage of more objective tools is that they have been validated in large trials, so there are outcomes with these subgroups of patients. The recently published Frailty Index was validated by using a large retrospective data set to evaluate three tools at the same time. These were the Katz Activity of Daily Living, the Lawton Instrumental Activity of Daily Living, and the Charlson Comorbidity Index. Outcomes generated by these measures were evaluated individually for their impact on survival, and no single test had an impact; however, when the three tools were combined in aggregate and stratified by hazard ratio, it was possible to combine them into a single scoring system that categorized patients as either fit, intermediate fit, or frail. The individual parts required for the Katz Activity of Daily Living and Lawton Instrumental Activity of Daily Living measurements are listed in Table 1 with their scoring components, and the aggregate scoring methodology is given in Table 2 . Age plays a role in the decision of whether to administer aggressive therapy to a patient; however, it is important also to consider the ability of a patient to perform the tasks measured in functional status assessments before being diagnosed with myeloma and how the symptoms of myeloma may contribute to a lack of functional status. As one considers using these functional assessments in older patients, recall that the question at hand is not whether a patient can tolerate the intensity of undergoing transplantation; rather, for many patients the question is whether they can tolerate therapy that includes a three-drug induction and then undergo a reduced-dose melphalan autologous transplantation (melphalan 140 mg/m 2 ). This difference in questioning is important because there is now strong evidence that older patients (age . 70 years) can well tolerate undergoing an autotransplantation as long as they receive a reduced dose of melphalan as part of the conditioning. 15 Dose reduction is the main reason why many myeloma transplant centers in the United States do not have an age cutoff for transplantation among patients with myeloma, 16 and it is not uncommon to have patients undergoing high-dose therapy at age 75 to 78 years. 17 Transplantation, or a functional status allowing for transplantation, is associated with improved overall survival (OS). How, then, does this influence therapy? If a patient is considered to be eligible for intensive therapy, a three-drug induction is likely optimal, with the immunomodulatory agent (IMID), proteasome inhibitor (PI), and dexamethasone combination being the first choice 18, 19 ; a secondary option is oral cyclophosphamide in conjunction with a PI or IMID and dexamethasone. 20 From the 2015 American Society of Hematology (ASH) Annual Meeting, it has become increasingly clear that a three-drug combination not only induces a better response, but that this improved response translates to an improvement in progression-free survival (PFS) and OS. 21 Although the first finding may have been expected-better depth of response leads to better PFS-the improvement in OS among a mixed group of patients (transplant and nontransplant) further supports the concept that more effective inductions result in better outcomes. When the SWOG 0777 study is compared with the study by Moreau et al, 22 also presented at the 2015 ASH Annual Meeting (bortezomib, thalidomide, and dexamethasone v bortezomib, cyclophosphamide, and dexamethasone), it seems that the IMID and PI combination is superior and should be the standard induction for suitable patients. If a patient is assessed as borderline by using a functional assessment, the three-drug induction may provide a clinical stress test that will help the treatment team to better appreciate whether intensive therapy should be part of a good care strategy. If patients are truly frail, there are a host of trials that suggest a two-drug regimen not only is better tolerated in the older, frail patient, but also has equivalent outcomes compared with a three-drug regimen. 23 In fact, it is likely that frailty accounts for why some induction trials show that two-and three-drug regimens are similar, whereas others show that two agents are superior. If one removes frail patients from the analysis, it becomes clear that three-drug induction is optimal if a patient is fit enough to receive this therapy.
Genetic Assessment
The second discriminator that has the potential to shape therapy is the genomic risk of the individual myeloma of each patient. Some form of genetic assessment is required at diagnosis for all patients, and this can be accomplished at a minimum with a myeloma FISH panel performed on tumor cells or GEP (Table 3) . 24 There are newer, evolving molecular diagnostics that will likely replace FISH and GEP and that are rapidly moving into clinical practice, such as targeted gene sequencing, RNA sequencing, or copy number arrays. 6 Identification of patients with high-risk myeloma represents part of the goal of genetic risk stratification. We know that identification of the 17p deletion, t(4;14), t(14;16), and t (14;20) requires longer durations of maintenance therapy, likely with three agents, as outcomes with single-agent lenalidomide or bortezomib are still suboptimal. 9, 25 However, as we begin to look at mutational profiles in myeloma, it is clear that some of the same mutations we see in other cancers, such as ras pathway, p53, and even B-raf mutations, also occur in myeloma 6 ; however, the functional and therapeutic importance of these mutations remains less clear. Although there are anecdotal data suggesting that B-raf mutations can be treated with the same agents used in melanoma and colorectal cancer, 26 the response rate and duration of response are limited. 27 Clinical use of these data is further complicated by recent reports suggesting that patients with B-raf mutations have similar OS compared with those with wild-type B-raf. This suggests B-raf may be a target, but it does not identify a high-risk subset when noted at the time of diagnosis. K-ras and n-ras are common mutations across all cancers, with only limited treatment options regardless of the tumor type. Furthermore, as we begin to understand clonal heterogeneity, it may be that only certain clones express some of these actionable mutations, which results in limited or no efficacy. These biologic findings support the use of combination therapy even in the face of known mutations, as it is unlikely that mutation-driven therapy alone will transform myeloma treatment.
There are limited data on the use of sequencing data to identify subsets of patients with good or poor outcomes; however, an article from the Medical Research Council suggests that certain mutations may predict for better response to induction compared with other mutations. This trial was limited by the use of older induction regimens that predominately contained alkylator agents, and much of what was identified to be predictors of poorer outcome resulted from the presence of mutations in DNA damage response genes, which was consistent with response to alkylator-based therapy. 28 The ongoing COMPASS (Clinical Outcomes in Multiple Myeloma to Personal Assessment of Genetic Profile) trial, which is evaluating the mutational profile at diagnosis and at subsequent relapse, is using sequencing technology in a cohort of 1,000 newly diagnosed patients with myeloma who are all receiving more modern induction therapy. This trial will provide additional data on how patterns of mutations may be used to identify either extraordinary responders or patients who are not likely to respond well toinduction or any therapy. 29 Additional patterns of mutations may predict for long or short duration of remission; however, longer follow-up with these modern induction regimens is needed to further identify and validate these findings. The interplay between mutational patterns and more recent immune-based treatments, such as elotuzumab, daratumumab, and checkpoint inhibitors, will also be of significant interest, as they may provide riskagnostic approaches to the treatment of plasma cell disorders.
The optimal induction regimen (IMID, PI, dexamethasone) is likely the same for standard-and high-risk patients from a practical approach (Fig 1) . Historically, it has been thought that because myeloma was indolent, a kinder, gentler approach was optimal for good-risk patients, as other approaches risked causing these patients harm; however, with modern and effective treatment, we know that these patients have the greatest chance for long-term PFS and perhaps even cure. Thus, to withhold highly effective therapy no longer makes sense. In contrast, we know that combination therapy is likely the best chance to suppress clonal evolution and to rapidly establish disease control in high-risk patients, which makes the three-drug induction the best choice. 30 In the era of increasingly effective inductions, the role and timing of transplantation continue to be debated. Several studies have demonstrated the ongoing benefit of autologous transplantation on PFS and OS, even when modern agents, such as lenalidomide and bortezomib, were used as part of the induction. It should be noted, however, that these were doublet-based inductions.
At the 2015 ASH Annual Meeting, the first analysis from theIntergroupeFrancophoneduMyélome-Dana-Farber Cancer Institute (IFM/DFCI) trial in which all patients received induction with lenalidomide, bortezomib, and dexamethasone followed by random assignment to early or delayed transplantation was presented. 31 From these data, it is clear that there continues to be a major benefit with early transplantation, even when optimal induction is used. When comparing the treatment regimen of lenalidomide, bortezomib, and dexamethasone followed by transplantation with that of the SWOG 0777 trial, it again becomes clear that transplantation adds significantly to the OS of patients, even when a modern triplet-based induction is used. These results have significant implications for patients treated in the United States, where suitable transplantationeligible patients often are not referred for stem-cell collection because of the belief that transplantation is no longer of any benefit to patients when highly effective induction therapy is available. The use of an optimal induction regimen followed by highdose therapy does not limit the ability to tailor therapy to patients. Once the initial induction and consolidation (with a transplant) are complete, there are likely to be opportunities to tailor therapy in the maintenance phase on the basis of genetics. IntheCancerandLeukemiaGroupB(CALGB)maintenancetrial of lenalidomide versus observation, PFS and OS benefits associated with lenalidomide maintenance were clear; however, the benefit in high-risk patients was short-lived, 32 and more aggressive three-drug maintenance may be an improvement. 9 Thus, if we consider how to use genetics to tailor therapy, it will likely not be at the induction phase but, rather, in the maintenance therapy setting that treatments are differentiated by what is identified at diagnosis to be the major risk factor.
FUTURE DIRECTIONS
The ability to identify a central, single targeted approach for the general management of cancer, and, in particular, myeloma, is a lofty goal, but it is one that is unlikely to be achieved. The genetics of cancer are such that, in most cases, many genetic abnormalities exist, and many different clones exist such that, outside of a disease such as chronic myelogenous leukemia, treatment with a single agent that targets a single mutation is not a good long-term strategy. In myeloma, the most effective agents target normal plasma cell biology (ie, the proteasome or cereblon), not cancer biology (ie, mutation-specific treatment); however, this is not likely to be the case for most human cancers. 33 As we consider how to tailor treatment to individual patients with myeloma, the current literature suggests that the use of biology-driven treatments, taking into account functional status and genetics, is likely the first and most important step. The incorporation of these agents with biology-based approaches will likely yield the best and most effective treatments as we continue to learn how best to target the many mutations found in patients with myeloma. 
